These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 28335769)

  • 1. Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda.
    Ramachandran A; Manabe Y; Rajasingham R; Shah M
    BMC Infect Dis; 2017 Mar; 17(1):225. PubMed ID: 28335769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis.
    Rajasingham R; Meya DB; Greene GS; Jordan A; Nakawuka M; Chiller TM; Boulware DR; Larson BA
    PLoS One; 2019; 14(1):e0210105. PubMed ID: 30629619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa.
    Jarvis JN; Harrison TS; Lawn SD; Meintjes G; Wood R; Cleary S
    PLoS One; 2013; 8(7):e69288. PubMed ID: 23894442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of the Implementation of Cryptococcal Antigen Lateral Flow Assay for the Diagnosis of Cryptococcal Meningitis in Symptomatic People Living With Human Immunodeficiency Virus in Brazil.
    Vianna CMM; Mosegui GBG
    Value Health Reg Issues; 2022 May; 29():53-59. PubMed ID: 34801886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam.
    Smith RM; Nguyen TA; Ha HT; Thang PH; Thuy C; Lien TX; Bui HT; Le TH; Struminger B; McConnell MS; Fanfair RN; Park BJ; Harris JR
    PLoS One; 2013; 8(4):e62213. PubMed ID: 23626792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.
    Rugemalila J; Maro VP; Kapanda G; Ndaro AJ; Jarvis JN
    Trop Med Int Health; 2013 Sep; 18(9):1075-1079. PubMed ID: 23937699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm
    Wykowski J; Galagan SR; Govere S; Wallis CL; Moosa MY; Celum C; Drain PK
    BMC Infect Dis; 2020 Jan; 20(1):61. PubMed ID: 31959112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis and budgetary impact of the Cryptococcal Antigen Lateral Flow Assay (CRAG-LFA) implementation for the screening and diagnosis of cryptococcosis in asymptomatic people living with HIV in Brazil.
    Vianna CMM; Mosegui GBG
    Rev Inst Med Trop Sao Paulo; 2021; 63():e57. PubMed ID: 34231822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.
    Vidal JE; Toniolo C; Paulino A; Colombo A; Dos Anjos Martins M; da Silva Meira C; Pereira-Chioccola VL; Figueiredo-Mello C; Barros T; Duarte J; Fonseca F; Alves Cunha M; Mendes C; Ribero T; Dos Santos Lazera M; Rajasingham R; Boulware DR
    Trop Med Int Health; 2016 Dec; 21(12):1539-1544. PubMed ID: 27699970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of fingerstick cryptococcal antigen lateral flow assay in HIV-infected persons: a diagnostic accuracy study.
    Williams DA; Kiiza T; Kwizera R; Kiggundu R; Velamakanni S; Meya DB; Rhein J; Boulware DR
    Clin Infect Dis; 2015 Aug; 61(3):464-7. PubMed ID: 25838287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
    Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
    Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.
    Longley N; Jarvis JN; Meintjes G; Boulle A; Cross A; Kelly N; Govender NP; Bekker LG; Wood R; Harrison TS
    Clin Infect Dis; 2016 Mar; 62(5):581-587. PubMed ID: 26565007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryptococcal antigen screening and early antifungal treatment to prevent cryptococcal meningitis: a review of the literature.
    Kaplan JE; Vallabhaneni S; Smith RM; Chideya-Chihota S; Chehab J; Park B
    J Acquir Immune Defic Syndr; 2015 Apr; 68 Suppl 3():S331-9. PubMed ID: 25768872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITY.
    Vidal JE; Boulware DR
    Rev Inst Med Trop Sao Paulo; 2015 Sep; 57 Suppl 19(Suppl 19):38-45. PubMed ID: 26465368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymptomatic Cryptococcal Antigenemia in People Living with HIV (PLHIV) with Severe Immunosuppression: Is Routine CrAg Screening Indicated in India?
    Anuradha S; H AN; Dewan R; Kaur R; Rajeshwari K
    J Assoc Physicians India; 2017 Apr; 65(4):14-17. PubMed ID: 28527158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the cost-per-result of a national reflexed Cryptococcal antigenaemia screening program: Forecasting the impact of potential HIV guideline changes and treatment goals.
    Cassim N; Coetzee LM; Schnippel K; Glencross DK
    PLoS One; 2017; 12(8):e0182154. PubMed ID: 28829788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cryptococcal antigen titre as a diagnostic tool and a predictor of mortality in HIV-infected patients with cryptococcal meningitis.
    Chen J; Zhang R; Shen Y; Liu L; Qi T; Wang Z; Mehraj V; Routy JP; Lu H
    HIV Med; 2019 Jan; 20(1):69-73. PubMed ID: 30311440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care.
    Rajasingham R; Meya DB; Boulware DR
    J Acquir Immune Defic Syndr; 2012 Apr; 59(5):e85-91. PubMed ID: 22410867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation.
    Jarvis JN; Govender N; Chiller T; Park BJ; Longley N; Meintjes G; Bekker LG; Wood R; Lawn SD; Harrison TS
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(6):374-9. PubMed ID: 23015379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.
    Liechty CA; Solberg P; Were W; Ekwaru JP; Ransom RL; Weidle PJ; Downing R; Coutinho A; Mermin J
    Trop Med Int Health; 2007 Aug; 12(8):929-35. PubMed ID: 17697087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.